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West Nile virus (WNV) mainly infects birds, horses and humans. Outcomes of the infection 
range from light uncharacteristic signs to fatal neurologic disease. The main objectives of the 
present study were to measure serum IgG and IgM antibodies in naturally exposed and 
vaccinated horses and to compare results of hemagglutination-inhibition test (HIT), enzyme-
linked immunosorbent assay (ELISA) and plaque reduction neutralization test (PRNT).  
Altogether 224 animals were tested with HIT for WNV antibodies and 41 horses were 
simultaneously examined with ELISA and PRNT. After primary screening for WNV 
antibodies, horses were vaccinated. Samples were taken immediately before and 3-5 weeks 
after each vaccination. McNemar chi-squared and percent agreement tests were used to detect 
concordance between HIT, ELISA and PRNT. 
Analyses by HIT confirmed the presence of WNV antibodies in 27/105 (25.71 %) from 
naturally exposed horses. Sera from 57/66 (86.36%) vaccinated animals were positive before 
the first booster and from 11/11 (100%) before the second booster. HIT was less sensitive 
when detecting IgG antibodies. We could detect post vaccination IgM in 13 cases with MAC-
ELISA and in 7 cases with HIT. 
WNV is endemic in Hungary causing regular natural infections. Protective antibodies could 
not be measured in each individual case 12 months after primary injections; protection is 
more reliable after the first yearly booster. Based on our findings it was not be possible to 
differentiate infected horses from recently vaccinated horses using IgM antibody 
capture ELISA (MAC-ELISA). HIT does not substitute ELISA or PRNT when detecting IgG, 
but was useful tool in this study to gain statistical information about the tendencies within a 
fixed population of horses. 
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1. Introduction 
West Nile virus (WNV) is a mosquito-borne zoonotic arbovirus belonging to the genus 
Flavivirus in the family Flaviviridae (Smithburn et al., 1940). It is transmitted in natural 
cycles between mosquitoes, (mainly the genus Culex), and wild birds (Bakonyi et al., 2013, 
Szentpáli-Gavallér et al., 2014, Pradier and Parker, 2014). Horses and humans are incidental 
and dead-end hosts; however they can develop severe neurological disorders (Kutasi et al., 
2011, Lim et al., 2011). Phylogenetic studies have identiﬁed 2 main lineages of WNV strains. 
Until the early 2000s strains from lineage 1 were present in Africa, India, and Australia and 
were responsible for outbreaks in Europe, in the Mediterranean Basin, and in North America, 
whereas lineage 2 strains had been reported only in sub-Saharan Africa and Madagascar. 
Circulation of WNV strains of lineage 2 have recently been reported in Hungary (Bakonyi et 
al., 2006), Austria (Wodak et al., 2011), Russia (Platonov et al., 2011), Romania (Sirbu et al., 
2011), Greece (Danis et al., 2011) and Italy (Savini et al., 2012). The Hungarian equine WNV 
outbreak - reported in 2008 - was the ﬁrst to be caused by a lineage 2 sub-Saharan strain in 
Europe. The pathogenicity of this lineage 2 strain resembled that of lineage 1 strains, and its 
sudden spread was unpredictable (Kutasi et al., 2011, Lim et al., 2011). 
The protective immune response to WNV requires both innate and adaptive immunity (Da 
Filette, 2012). The importance of adaptive immunity has been demonstrated as passive 
transfer of immune monoclonal and polyclonal antibodies protected mice from lethal WNV 
infection (Diamond et al., 2012). IgM is critically important for the control of early WNV 
infection and is detectable approximately 4 to 7 days after infection. After four to five days of 
illness, IgG antibodies are measurable in patients presumably conferring long-term protection 
against WNV re-infection (Tardei et al., 2000). Cellular immune responses also control WNV 
infections. Cytolytic T cells clear WNV infection by lysing infected cells. (Da Filette et al., 
2012) 
Antibodies can be identified in equine serum by IgM capture enzyme-linked immunosorbent 
assay (ELISA), haemagglutination inhibition test (HIT), IgG ELISA, plaque reduction 
neutralisation test (PRNT), and microtitre virus neutralisation (VN) (Beaty et al., 1989; 
Hayes, 1989). Virus-neutralizing antibody responses persist for longer than WNV-specific 
IgM levels in serum. The duration of IgM appears to be short-lived in horses; hence it is 
useful for identifying and differentiating recent infections from previously exposed animals. 
Horses infected with either WNV lineage 1 or lineage 2 elicit a similar antibody profile in 
serum samples and there is not any notable differences in the antibody profile (Castillo-
Olivares et al., 2011). 
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The emergence of lineage 2 strains of WNV in Europe as a cause of clinical disease and 
mortality in horses raised the question whether the existing WNV vaccines - which are all 
based on lineage 1 strains - protect against circulating lineage 2 strains of WNV. Up until now 
the lineage 1 vaccines turned out to be effective in protecting against lineage 2 strains of the 
disease as well (Minke et al., 2011). 
The main objectives of the present study were to measure serum IgG and IgM antibodies in 
naturally exposed and vaccinated horses and to compare results of HIT, competitive ELISA 
and PRNT. 
 
2. Materials and methods 
Altogether we examined 224 horses for the presence of WNV antibodies. Two different 
examinations were performed (Table 1.). In the first examination after collecting a primary 
sera sample for WNV antibodies 182 animals were vaccinated with an inactivated virus 
vaccine according to the user’s manual of the product (Duvaxyn® WNV, Pfizer, in the EU 
now Equip® WNV, Zoetis; in the US WEST NILE-INNOVATOR®, Zoetis). Out of th182 
horses 105 animals were naturally exposed and 77 had been vaccinated before. Naturally 
exposed horses without showing any clinical signs were randomly selected in different parts 
of the country. Samples were collected from diverse parts of the country, but the majority of 
samples originated from the central region of Hungary. Of the 77 immunized animals 66 were 
given the two primary vaccinations approximately 12 months ago and 11 were already 
vaccinated for 2 subsequent years. Based on the results of the primary samples (prior to 
vaccination), horses were divided into four groups: group A contained horses that were 
previously seronegative and the horses in group B were seroconverted secondary to natural 
infection. Group C incorporated horses that were previously vaccinated with the available 
West Nile inactivated virus vaccine for one year (n=66) with a double primary vaccination 
and horses in group D (n=11) had been vaccinated for two years with a plus booster in the 
second year. Sera samples were collected three times from Group A and B, the first ones 
immediately prior to the primary vaccination, the second ones were collected 3 weeks later – 
immediately prior to the second dosage – and the final samples 3-5 weeks after the second 
dosage. Sera samples were collected two times from horses in Group C and D, first 
immediately prior to the booster and the second 3-5 weeks after the booster. All sampling and 
vaccination took place in March and April to avoid recent seroconversion from natural 
infection and to finish vaccination protocol in time before the WNV season. Based on other 
papers clinical cases in Europe occur between August and November (Kutasi et al., Monaco 
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et al., 2010). Horses should be immunised prior to the mosquito season, in order to achieve a 
sufficient protection with the inactivated WNV vaccine. 
 
At the time of the sera sample collection there were no ELISA or capture ELISA kits 
available in Hungary, so on the first occasion our samples were tested by the National Centre 
for Epidemiology, where IgG levels were measured with HIT validated for human screening. 
The HIT was performed as described by Clarke and Casals, with a microtitre-plate format. 
We briefly summarize the key steps of the method. Nonspecific inhibitors and natural 
hemagglutinins were removed by kaolin adsorption. Dilutions of kaolin treated equine serum 
were mixed with 8 hemagglutination (HA) units of suckling mouse WNV antigen and 
incubated at 4°C overnight. Goose erythrocytes were then added to the mixture, and the 
solution was incubated for an additional hour at room temperature (Clarke and Casals, 1958). 
The HIT titre was determined as the highest dilution of equine serum that caused complete 
inhibition of erythrocyte agglutination by 8 HA units of viral antigen. IgG test was considered 
positive when titre was equal or higher than 1:40.  
Although HIT it is still used in laboratories, this test is gradually being replaced by other 
techniques. The disadvantage of HIT is the increasing tendency with time for sera to cross-
react with other virus antigens within a given virus family (Specter et al., 2000). Therefore in 
our study 41 horses were simultaneously examined for both IgG and IgM with ELISA and 
also with PRNT. IgM antibody capture ELISA (MAC-ELISA), competitive ELISA tests and 
PRNT were used according to the OIE Terrestrial Manual 2013. Equine serum samples were 
tested at dilution of 1/400. All samples were examined for IgG but only post vaccination 
samples were tested for IgM. 
HIT intervals were calculated with two sample z tests at 0.95 confidence levels. McNemar 
chi-squared and percent agreement tests were used to detect concordance between HIT, 
ELISA and PRNT. We calculated sensitivity and specificity values for both HIT and ELISA 
taking PRNT results as reference values.  
During the second examination, 42 out of the 224 cases were evaluated for seroprevalence no 
further tests were carried out. The selection of this group of 42 horses was restricted to areas 
of the country where previously WNV disease was detected since our intention was to look 
for subclinical seroconversion rates by measuring the IgG titer with HIT.   
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Table 1: Summary of the examinations 
 
3. Results 
3.1. I examination 
3.1.1. HIT 
Before presenting our results, we call the attention of the reader to averages shown in our 
tables and figures were calculated on a logarithmic scale. The rationale behind this method 
was to avoid a few extremely high (1:5120 and higher) values heavily altering our results. 
Since one cannot assign any biological significance to these outstanding values (i.e., we 
cannot assume that a horse with 1:10240 IgG titer is better protected against the disease than 
one with 1:5120 IgG titer), reducing their effect on the averages by moving to the logarithmic 
scale seemed a more relevant approach. By the same argument one can conclude that the 
averages themselves, regardless of the method they were calculated with, contain little 
information about the studied groups. To remedy this we will provide some additional 
descriptive statistics. 
Groups Horses (n)  
             I. examination 
Group A 
no vaccination history , 
seronegative 
78 
Group B 
no vaccination history , 
seropositive 
27 
Group C 
vaccination history of 1 year 
66 
Group D 
vaccination history of 2 years 
11 
II. examination  
Not vaccinated 
horses 
42 
Altogether 224 
7 
 
Altogether we examined 105 horses with no vaccination history. According to the IgG titre of 
the primary serology test we divided these horses into groups A (n=78) and B (n=27). Based 
on these results 74.29 % of the naturally exposed horses were seronegative and 25.71 % were 
seropositive. According to statistical analysis (two sample z-test, 0.95 confidence level) the 
rate of seropositive horses is between 16-38%. Following the first vaccination 65 (83.33%) of 
78 horses in Group A seroconverted and all horses of group B remained seropositive. 
Sequentially to the second vaccination in group A 76 (97%) seropositive and 2 seronegative 
horses were observed, and in group B all horses were seropositive (Tables 2. and 3.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1. sera sample (prior 
to vaccination) 
2. sera sample (after 
first vaccination) 
3. sera sample (after 
second vaccination) 
 positive negative positive negative positive negative 
Number of horses 0 78 65 13 76 2 
Ratio 0% 100% 83.33% 16.67%% 97.44% 2.56% 
Titre averages
a - <1:10 
1:160-
1:320 
<1:10 
1:640-
1:1280 
1:10-1:20 
Table 2: Summery of IgG levels from horses in Group A (n=78) 
 1. sera sample (prior 
to vaccination) 
2. sera sample (after 
first vaccination) 
3. sera sample (after 
second vaccination) 
 positive negative positive negative positive negative 
Number of horses 27 0 27 0 27 0 
Ratio 100% 0% 100% 0% 100% 0% 
Titre averages
a 1:40-1:80 - 
1:640-
1:1280 
- 
1:2560-
1:5120 
- 
Table 3: Summery of the IgG levels from horses in Group B (n=27) 
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We also present a figure showing the ratio of horses with measured antibody levels 1:20 or 
lower, between 1:40 and 1:160, and 1:320 or higher (we refer to these three categories as 
negligible, satisfying and high respectively) (Figure 1.). 
Altogether 77 horses had a history of vaccination, of these 66 had received primary 
vaccination in the previous year (group C) and 11 were vaccinated twice during the previous 
two years (group D). Group C consisted of 9 (13.64%) seronegative and 57 (86.36%) 
seropositive horses. In group D all horses were seropositive.  
Following the first vaccination in group C 65 (98.48%) seropositive and 1 (1.52%) 
seronegative horses were found. All of the IgG levels of seropositive horses except for one 
were higher than 1:320. In group D all horses remained seropositive, with 1:640 or higher IgG 
titres (Tables 4. and 5.). For easier comparison we summarized the results of each group in 
Figure 2. 
 
 
 
 
 
 
 
 
 
Table 4: Summary of group C IgG levels 
 
 
 
 1. sera sample (prior 
to vaccination) 
2. sera sample (after first 
vaccination) 
 positive negative positive negative 
Number of horses 11 0 11 0 
 1. sera sample (prior to 
vaccination) 
2. sera sample (after the 
vaccination) 
 positive negative positive negative 
Number of horses  57 9 65 1 
Ratio 86.36% 13.64% 98.48% 1.52% 
Titre averages
a   1:320-1:640 <1:10 1:2560-1:5120 
1:10-
1:20 
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Ratio 100% 0% 100% 0% 
Titre averages
a
 
1:320-
1:640 
- 
1:2560-
1:5120 
- 
Table 5: Summary of group D IgG levels  
 
3.1.2. ELISA/PRNT/ HIT  
Altogether 90 sera samples were examined for IgG levels, which we obtained from the 41 
horses as shown in Table 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6: Sera samples used for the comparison of HIT/ELISA/PRNT 
 
 
The table below compares the IgG results from ELISA/PRNT/HIT (Table 7). Overall the 3 
tests yielded the same result in 74 of the 90 cases (82%).  
 
 
HIT+ 
PRNT+ 
HIT+ 
PRNT – 
HIT – 
PRNT+ 
HIT – 
PRNT – 
ELISA+ 63 0 10 1 
Groups Number of 
horses 
Sera samples 
per horses 
Sera samples  
per groups   
Group A 7 3 21 
Group B 7 3 21 
Group C 
seronegative prior to buster 
vaccination 
7 2 14 
Group C  
seropositive prior to buster 
vaccination 
7 2 14 
Group D  7 2 14 
Horses from II. 
examinations 
 
6 1 6 
Altogether 7*3+7*3+7*2+7*2+7*2+7*2+6*1 90 
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ELISA – 0 1 4 11 
Table 7: IgG results from ELISA/PRNT/HIT  
(Green numbers show the values where all three results agree and red numbers indicate the 
cases when one test gave a different value from the others) 
 
We provide contingency tables for pairwise comparison of the three methods, below each 
table we indicate overall percent agreement (Table 8./ A, B, C). 
 
 
HIT+ HIT- 
ELISA+ 63 11 
ELISA – 1 15 
Table 8. /A: Contingency table of ELISA/HIT 
(63+15)/90 : 87% 
 
 
PRNT+ PRNT – 
ELISA+ 73 1 
ELIS – 4 12 
Table 8. / B: Contingency table of ELISA/PRNT 
85/90 : 94% 
 
 
Table 8/ C: Contingency table of HIT/PRNT 
75/90 : 83% 
 
We used McNemar's test (with continuity correction) to verify that the difference shown in 
the contingency tables is significant. The result of the test is that both ELISA and HIT (p = 
0.0094, McNemar's chi-squared = 6.750, df = 1) and HIT and PRNT (p = 0.0019, McNemar's 
chi-squared = 9.6, df = 1) differ (very) significantly, while the test does not show a significant 
difference between ELISA and PRNT results (p = 0.3711, McNemar's chi-squared = 0.8, df = 
1). 
 
PRNT+ PRNT – 
HIT+ 63 1 
HIT – 14 12 
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We calculated sensitivity and specificity values for both HIT and ELISA taking PRNT results 
as reference values (These are just the positive/negative percent agreements from the above 
contingency tables) Sensitivity was 82% and specificity was 92% for HIT, while sensitivity 
was 95% and specificity was 92% for ELISA (Table 9). 
Comparison  Sensitivity Specificity 
PRNT / HIT 63/(63+14) = 82% 12/(12+1) = 92% 
PRNT / ELISA 73/(73+4) = 95% 12/(12+1) = 92%  
Table 9: Sensitivity and specificity values  
 
Only the post vaccination samples were tested for IgM with Capture ELISA. We detected 13 
IgM positive samples. 
 
3.2. II examination  
42 of the horses were not participating in the vaccination program, in these cases we 
investigated if the horses had seroconversion due to natural infection. 
40 of the horses examined previously shared a stall with confirmed cases of neuroinvasive 
WNV infection. 27 horses out of the 40 were seronegative and 13 were seronegative. 
Two of the 42 horses were survivors of neuroinvasive WNV, both confirmed by high IgG and 
IgM levels at the acute phase of the disease. One of these two cases was shown no humoral 
protection against WNV 3 years after infection; the other horse had sufficient level of IgG 
(1:160), 1 year after infection, to be able to prevent a re-infection.   
4. Discussion 
The sera sampling prior to vaccination was performed in March, when there was a negligible 
chance of a recent infection, due to the seasonal nature of the disease (Smithburn et al., 1940). 
Therefore the 25.71% of IgG positive samples, from the horses with no vaccination history, 
were due to infections from previous year(s). 
Although HIT was the least sensitive (82 %) serological test we performed to measure IgG 
levels and the sample of 105 horses (Group A and B) is not suitable to give an accurate 
account of the rate of seropositive horses in the whole Hungarian horse population, we can 
still conclude that there is a high seroconversion rate in the country. According to statistical 
analysis (two sample z-test, 0.95 confidence level) the rate of seropositive horses is between 
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16-38%. While this is clearly not a very accurate estimate, even the lower end of the 
estimated interval (16%) would indicate a high seroconversion rate in the country.   
According to the vaccine description only 1 booster is needed per year following the primary 
vaccination course (2 subsequent vaccinations in 3 weeks intervals) in order to maintain a 
sufficient immunity (EMA/510730/2008). Also it was reported that the immune response after 
the booster is stronger compared to the primary vaccination (EMEA, 2008). We found that all 
horses from group D had 1:80 or higher IgG levels prior to the booster and 9 out of 11 horses 
had 1:320 or higher, so we concluded that all horses could indeed maintain their immunity for 
one year in this group. On the contrary, not all horses show humoral protection prior to 
booster vaccination from group C. That is, horses in this group did not always maintain their 
immunity for 12 month. With the possibility of climate change affecting the seasonal nature 
of the disease this result could become significant for veterinary practice in the future. Due to 
climate change WNV might appear in other parts of the year than early autumn. 
Consequently, vaccination which induces a protection during the whole year would be 
beneficial. Since it was verified by all three serological methods in this study that some horses 
lose protective level of antibody in less than 12 months after the primary vaccination, we 
suggest that the first booster should be applied sooner. 
Comparing the post vaccination titres we found that the IgG average levels of groups A and B 
and groups C and D did not significantly diverge. Taking a closer look at the actual 
distribution of the values within the groups, we found that data from groups C and D showed 
a more homogeneous profile; hence the post-vaccination IgG levels in these groups were 
more reliably in the high domain than those of the horses vaccinated for the first time in the 
year of the study.   
We do not have accurate knowledge of how the IgG levels predict the length of the immunity; 
however our results suggest a hypothesis, that one should expect the presence of antibodies to 
persist if the initial IgG level is sufficiently high. Naturally to make such a hypothesis 
quantitative and to confirm it one would need to conduct a longitudinal study. 
Hemagglutination is a general property of the arbovirus group where WNV also belongs. 
(Sabin, 1951) The descriptive statistics indicate that the HIT is less sensitive than the ELISA 
and PRNT. However it is worth noting that out of the 14 cases where the PRNT result was 
positive and the HIT result was negative, 11 cases gave border PRNT results. According to 
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these results HIT is not a sufficient method to detect slightly elevated, border positive 
antibody titres. 
Some strains of a given virus may show greater capacity than others to yield an HA antigen 
(Clarke and Casals, 1958). Based on this, sensitivity of the HIT does not only depend on the 
test itself but also on the WNV strain. 
All members of the genus Flavivirus share antigenic epitopes, as revealed by cross-reactivity 
in the HIT (Casals et al., 1954). Therefore, commercially available plates, not necessarily 
coated with homologous antigen, can be used for antibody detection in serum by ELISA. Both 
HIT and ELISA should be followed by a neutralization assay to complete identification within 
the serologic group (Hann et al., 2003). However, PRNT is a laborious test and must be 
carried out in a biosafety level 3 (BSL-3) facility as viable WNV are used in this assay (Da 
Filette et al., 2012). ELISA has the advantage of being rapid, reproducible and less expensive 
than other methods. 
In two cases from group A even the second vaccination and in one case from group C even 
the booster vaccination did not induce humoral immunity, according to the HIT results. 
Besides the lower sensitivity rate of HIT compared to ELISA or PRNT, this phenomenon 
could also be explained by a possible immune tolerance or immunosuppression of these 
horses, which can lead to a low- or non-reactivity of the immune system. While immune 
tolerance describes a state of unresponsiveness of the immune system to particular agents 
(Garnett et al., 2011) immunosuppression generally reduces or eliminates an immune 
response to all antigen stimuli. The most common iatrogenic cause of corticosteroid treatment 
is immunosuppression, which can bias adaptive immune response to vaccination in horses 
(Slack et al., 2000). 
IgM can be detected after a recent infection, approximately for 4 to 7 days (Tardei et al., 
2000). All of our samples were collected between March and April when there is a negligible 
chance of a recent infection, therefore the 13 post vaccination IgM positive results detected 
with capture ELISA, could only develop secondary to the vaccination. So we can conclude 
that the presence of IgM is not indicating natural WNV infections, as it has been already 
reported in a previous study (Jonquiere, 2010).  
In the second examination we tested for seroconversion due to natural infection, on 40 cases, 
which previously shared a stall with confirmed cases of neuroinvasive WNV infection. 32.5 
% of the studied cases were seropositive. This is a higher value compared to our findings in 
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the first examination’s naturally exposed cases (25.71%), but according to statistical analysis 
(two sample z-test, 0.9 confidence level) the difference between the two measured value is not 
significant. Based on this it is not possible to rule out that horses coming from environments 
where infected horses were detected are not more exposed to the disease, but to confirm or 
reject this statement a larger sample would be needed. 
Among flaviviruses, Yellow fever virus results in a lifelong natural immunity. In contrast 
protection against Japan encephalitis virus (JEV) or WNV may lessen later in lifetime (Parker 
et al., 2003). 
Our result was in accordance with this, since from the two horses which survived from 
neuroinvasive WNV infection only one had a protective level of IgG, which was latter 
infected. 
Lack of or lower humoral immune protection following a natural infection does not imply that 
the horse does not have a cellular immunity. A possible way of evaluating cellular immunity 
in these cases could be an investigation of the cytotoxic, necrotising effect of the T-killer 
cells.  
Effective vaccine-mediated protection against WNV disease will most likely require both 
virus-specific antibody and cell-mediated immune responses. Many groups have reported 
flavivirus vaccine candidates that can efficiently induce virus-specific antibody responses, but 
the induction of appropriate T cell responses have been less frequently reported. In this 
regard, live attenuated vaccines have been shown to be very effective for inducing high 
magnitude, virus-specific T cell responses (Nelson 2010). 
 
5. Conclusions  
The ratio of seropositive horses is high in Hungary. There were cases where protective 
antibodies could not be measured in 12 months after primary vaccination; therefore we 
suggest that the first booster should be repeated earlier than a year after. Flavivirus infected 
sera show cross-reactions in serodiagnosis with heterologous flavivirus infections. Therefore 
PRNT is still used as the reference assay for specific diagnosis of WNV infection. ELISA has 
the advantage of being a faster and less expensive alternative which is more accessible for 
everyday use. HIT is not suitable for diagnostics; however it was a useful tool in this study to 
gain statistical information about the tendencies within a fixed population of horses. Based on 
our findings it was not possible to differentiate infected horses from recently vaccinated 
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horses using the MAC-ELISA. Following neuroinvasive infections there is no available data 
about the duration of protective humural or cellular immunity. 
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a
 As it has been explained at the start of this section, averages have been calculated on a 
logarithmic scale. Due to the size of the error we indicate the magnitude of the averages in 
each table rather than the actual values. 
 
 
